Resistance treatment of eltrombopag/eltrombopag

Eltrombopag/Eltrombopag is a thrombopoietin receptor agonist, commonly used to treat chronic immune (idiopathic) thrombocytopenia, aplastic anemia (AA) and other diseases. However, with prolonged use, some patients may develop resistance to eltrombopag, resulting in reduced or even ineffective treatment. Methods to deal with eltrombopag resistance mainly include:

1. Strengthen drug treatment monitoring: timely detect signs of drug resistance through clinical testing and pharmacokinetic indicators. This helps doctors adjust treatment plans in a timely manner to avoid worsening of the condition.

2. Adjust the treatment plan: Once drug resistance occurs, doctors need to adjust the drug dosage or replace other treatment drugs according to the patient's specific situation. For example, consideration may be given to switching to other types of thrombopoietin receptor agonists, or to using other drugs in combination to enhance efficacy.

3. Strengthen patient medication education: Improve patients’ awareness and understanding of medications, and guide patients to use medications correctly and rationally. This helps reduce unnecessary drug resistance reactions and improves treatment effectiveness.

4. Establish a drug resistance registration system: record the drug resistance status of patients in a timely manner to provide reference for future treatment. This helps doctors better understand the patient's condition and medication history and develop a more personalized treatment plan.

In the process of dealing with eltrombopag resistance, patients should actively participate in and follow medical instructions. Do not blindly adjust the drug dosage or change the drug yourself to avoid adverse reactions or affecting the treatment effect. At the same time, maintaining good living habits and mentality can also help improve treatment effects and reduce the occurrence of drug resistance.